Performance of 4 Automated SARS-CoV-2 Serology Assay Platforms in a Large Cohort Including Susceptible COVID-19-Negative and COVID-19-Positive Patients
AuthorWard, Matthew D
Mullins, Kristin E
Christenson, Robert H
JournalJournal of Applied Laboratory Medicine
PublisherOxford University Press
MetadataShow full item record
AbstractBACKGROUND: Anti-SARS-CoV-2 serological responses may have a vital role in controlling the spread of the disease. However, the comparative performance of automated serological assays has not been determined in susceptible patients with significant comorbidities. METHODS: In this study, we used large numbers of samples from patients who were negative (n = 2030) or positive (n = 112) for COVID-19 to compare the performance of 4 serological assay platforms: Siemens Healthineers Atellica IM Analyzer, Siemens Healthineers Dimension EXL Systems, Abbott ARCHITECT, and Roche cobas. RESULTS: All 4 serology assay platforms exhibited comparable negative percentage of agreement with negative COVID-19 status ranging from 99.2% to 99.7% and positive percentage of agreement from 84.8% to 87.5% with positive real-time reverse transcriptase PCR results. Of the 2142 total samples, only 38 samples (1.8%) yielded discordant results on one or more platforms. However, only 1.1% (23/2030) of results from the COVID-19-negative cohort were discordant. whereas discordance was 10-fold higher for the COVID-19-positive cohort, at 11.3% (15/112). Of the total 38 discordant results, 34 were discordant on only one platform. CONCLUSIONS: Serology assay performance was comparable across the 4 platforms assessed in a large population of patients who were COVID-19 negative with relevant comorbidities. The pattern of discordance shows that samples were discordant on a single assay platform, and the discordance rate was 10-fold higher in the population that was COVID-19 positive.
Rights/Terms© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: firstname.lastname@example.org.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16405
- Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2.
- Authors: Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, McLawhon RW, Voss JE, Nemazee D, Fitzgerald RL
- Issue date: 2021 Jan 30
- Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories.
- Authors: Plaga A, Wei R, Olson E, Payto D, Harrington J, Nwe-Kissig PT, Strizzi M, Zilka S, Ko J, Colón-Franco JM
- Issue date: 2021 Jul 7
- Analytical and Clinical Analysis of Two Automated Anti-SARS-CoV-2 Immunoassays in Pre-Pandemic and Pandemic Patient Populations.
- Authors: Yang J, Pederson EC, Hamilton C, Neibauer T, Robyak K, McGhee P, Speicher T, Zhu Y
- Issue date: 2021 Mar 1
- Assessment of commercial SARS-CoV-2 antibody assays, Jamaica.
- Authors: Butterfield TR, Bruce-Mowatt A, Phillips YZR, Brown N, Francis K, Brown J, Walker JP, McKnight NAL, Ehikhametalor K, Taylor DK, Bruce CA, McGrowder D, Wharfe G, Sandiford SL, Thompson TK, Anzinger JJ
- Issue date: 2021 Apr
- Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies.
- Authors: Hubbard JA, Geno KA, Khan J, Szczepiorkowski ZM, de Gijsel D, Ovalle AA, AlSalman AS, Gallagher TL, Johnston AA, Tibbetts AR, Vital SE, Cervinski MA, Nerenz RD
- Issue date: 2021 Mar 1